Background: CBL0137 is a novel drug that modulates FAcilitates Chromatin Transcription (FACT), resulting in simultaneous nuclear factor-B suppression, heat shock factor 1 suppression and p53 activation. CBL0137 has demonstrated antitumor effects in animal models of several adult cancers and neuroblastoma. 
INTRODUCTION
CBL0137 is a member of a new class of anticancer drugs, named curaxins, that modulate important pathways involved in the pathogenesis of cancer. CBL0137 is reported to activate TP53 and inhibit cellular stress Abbreviations: %hCD45+, percentages of human CD45-positive; ALL, acute lymphocytic leukemia; C max , maximum plasma concentration; EFS T/C, ratio of event-free survival treated/control; FACT, Facilitates Chromatin Transcription; HSF-1, heat shock factor 1;
(NOD)/scid −/− , nonobese diabetic/severe combined immune deficient; NF-B, nuclear factor-B; PPTP, Pediatric Preclinical Testing Program; rIC 50 , median relative IC 50 pathways mediated by nuclear factor-B (NF-B) and heat shock factor 1 (HSF-1). [1] [2] [3] It is considered that apoptosis induced by CBL0137 is mediated through inhibition of FAcilitates Chromatin Transcription (FACT), a chromatin remodeling complex composed of SSRP1 and SUPT16H subunits. 1 This complex is involved in the transcription of genes with highly ordered chromatin structure that are essential for replication and mitosis. [4] [5] [6] Curaxins bind DNA without inducing damage or activating DNA damage-sensitive pathways, but they alter DNA topology sequestering FACT on DNA, making it unable to bind histones that regulate normal chromatin remodeling. 1 FACT is overexpressed in several tumor types (e.g. pancreatic ductal carcinoma and lung carcinoma) relative to paired normal tissue and associated with a more aggressive phenotype with an overall poor survival. 7 Less is known about FACT expression in pediatric cancer. Overexpression of the SSRP1 subunit was associated with an 11q12 amplicon in an anaplastic medulloblastoma. 8 Carter et al. 9 observed downregulation of MYCN when either SSRP1 or SUPT16H subunits of FACT were suppressed, suggesting that FACT may regulate the expression of MYCN in neuroblastoma cell lines. FACT is expressed in early embryogenesis and undifferentiated progenitors and stem cells of adult tissues. In contrast, FACT subunit proteins are poorly detected in differentiated tissues. 10 The role of NF-B in cancer is well established. 11 This transcription factor is constitutively activated in acute lymphoblastic leukemia (ALL), 12 and activation of the classical pathway is considered as one factor in suppression of differentiation in rhabdomyosarcoma 13 and suppression of apoptosis in murine B lymphocytes, Hodgkins lymphoma cells and some breast cancer cell lines. 14-16 NF-B is also associated with drug resistance in neuroblastoma cells, 17 
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MATERIALS AND METHODS
In vitro testing:
In vitro testing was performed using DIMSCAN, as previously described in a characterized panel of 24 cell lines. 20 Cells were incubated in the presence of CBL0137 for 96 hr at concentrations ranging from 1.0 nM to 10 M and analyzed as previously described. 21 In vivo tumor growth inhibition studies: CB17SC scid −/− female mice (Taconic Farms, Germantown, New York) were used to propagate subcutaneously implanted kidney/rhabdoid tumors, sarcomas (Ewing, osteosarcoma, rhabdomyosarcoma), neuroblastoma and nonglioblastoma brain tumors, while BALB/c nu/nu mice were used for glioma models, as previously described. 22 Human leukemia cells were propagated by intravenous inoculation in female nonobese diabetic (NOD)/scid −/− mice, as described previously. 23 Female mice were used irrespective of the patient gender from which the original tumor was derived. All mice were maintained under barrier conditions and experiments were conducted using protocols and conditions approved by the institutional animal care and use committee of the appropriate consortium member. Eight to 10 mice were used in each control or treatment group. Tumor volumes (cm 3 ) (solid tumor xenografts) or percentages of human CD45-positive (%hCD45+) cells (ALL xenografts) were determined and responses were determined using three activity measures, as previously described. 22 An in-depth description of the analysis methods is included in Supplementary Appendix S1.
Statistical methods:
The exact log-rank test, as implemented using Proc StatXact for SAS R , was used to compare the event-free survival (EFS) distributions between treatment and control groups. P values were two-sided and not adjusted for multiple comparisons, given the exploratory nature of the studies.
Drugs and formulation: CBL0137 was provided to the Pediatric Preclinical Testing Program by Cleveland BioLabs Inc. through the Cancer Therapy Evaluation Program (NCI). CBL0137 was formulated in 5% dextrose, with a working solution of 10 mg/ml and dosing at 0.05 ml per 10 g body weight. CBL0137 was administered by intravenous injection weekly for four consecutive weeks. The total planned treatment and observation period was 6 weeks. Both dose and schedule were proposed by the drug supplier based on mice toxicology studies. 
RESULTS
In vitro testing
Int CR
a EFS T/C value is defined by the ratio of the median time to event of the treatment group and the median time to event of the respective control group. High activity requires the following: (i) an EFS T/C > 2; (ii) a significant difference in EFS distributions; and (iii) a net reduction in median tumor volume for animals in the treated group at the end of treatment as compared to at treatment initiation. Intermediate activity demonstrates criteria (i) and (ii) above, but not having a net reduction in median tumor volume for treated animals at the end of the study. Low activity demonstrates EFS T/C < 2. b Objective response measures are described in detail in the Supplementary Appendix S1. PD1 is progressive disease with EFS T/C ≤ 1.5 and PD2 is progressive disease with EFS T/C > 1.5. Of these six models, five were wild type for TP53. However, 12 other solid tumor models wild type for TP53 were unresponsive (i.e. PD1 responses) to CBL0137. 
DISCUSSION
Curaxins represent novel anticancer agents that simultaneously activate TP53 and suppress survival pathways such as NF-B.
CBL0137 has been reported to have significant activity against various In vivo, CBL0137 was well tolerated at the dose and schedule used.
Against solid tumor models, the activity of CBL0137 was modest with some delay in tumor growth (PD2) in six models, but the overall activity was low. These data are consistent with the results using pancreatic carcinoma xenograft models wherein tumor growth inhibition varied from approximately 20 to 60%. 19 Of note, none of five neuroblastoma xenografts responded significantly to CBL0137 treatment in contrast to the TH-MYCN transgenic and BE(2)-C xenograft models previously reported. 9 In the latter report, a higher dose of CBL0137
(60 mg/kg) with more frequent dosing (every 4 days) was employed compared with that used by the PPTP (50 mg/kg every 7 days).
CBL0137 demonstrated greater activity against leukemia models, with
PRs measured in three B-precursor ALL, one T-cell and a CR in an infant MLL model. Of note, the responding ALL models had relatively low-level expressions of both SSRP1 and SUPT16H (that encodes SPT16), considered as markers for sensitivity when expressed at high levels. 19 In contrast, KT-13 (Wilms tumor) expressed the highest level of SUPT16 and had a high-level expression of SSRP1 but a poor response (PD1, T/C EFS = 1.6). Thus, the major activity against these 
